



PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting

April 12, 2021

RNS Number : 0542V
PureTech Health PLC
12 April 2021

12 April 2021

PureTech Health plc

PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting

Novel antibody demonstrates highly specific and highly potent targeting of immunosuppressive $\gamma\delta 1$ T cells from cancer patients

Enriched in many intractable solid tumors and blood of cancer patients, $\gamma\delta 1$ T cells represent important new target for cancer immunotherapy

[PureTech Health plc](#) (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of a scientific poster detailing additional promising preclinical results for its LYT-210 antibody at the 2021 American Association for Cancer Research (AACR) Annual Virtual Meeting.

LYT-210 is a novel, fully human monoclonal antibody (mAb) directed against T cells bearing $\gamma\delta 1$ receptors, which are known to suppress the anti-tumor immune response. The new research shared at AACR demonstrates that LYT-210 is both highly specific and highly potent, rapidly inducing cell death of immune-suppressive $\gamma\delta 1$ T cells, while sparing other T cells that play important roles in a healthy immune response. The research was conducted in vitro using both patient blood and cancer tissue. LYT-210 has potential as either a single agent or in combination with checkpoint inhibitors and other anti-cancer treatments.

"The role of $\gamma\delta 1$ T cells in cancer immune suppression has come into sharp focus in recent years. We now know that these cells deploy multiple immunosuppressive signals to dampen the anti-tumor response and enable the cancer to grow and spread," said Aleksandra Filipovic, M.D. Ph.D., Head of Oncology at PureTech. "We are excited by these new data demonstrating that our LYT-210 therapeutic candidate can precisely target and swiftly deplete pathogenic $\gamma\delta 1$ T cells. We believe that removing these culprits from the tumor microenvironment systemically may have the potential to reawaken the immune system and contribute to a strong anti-tumor response. Moreover, both we and others in the field have established that a heightened presence of pathogenic $\gamma\delta 1$ T cells in tumor tissue and blood is correlated with more aggressive disease, poorer response to some therapies and a lower chance of survival. Given those links, we believe that the biomarker-centric approach we are developing as part of our $\gamma\delta 1$ T cell program may have the potential to identify and select the patients who are most likely to benefit from LYT-210 in the clinic and beyond."

$\gamma\delta 1$ T cells are upregulated in multiple solid tumors including breast cancer, glioblastoma, melanoma and pancreatic cancer. They suppress the immune response through multiple mechanisms, including blocking

effector T cells, hindering antigen-presenting dendritic cells, restricting the anti-tumoral activity of $\gamma\delta 2$ T cells and attracting tumor-associated macrophages and myeloid-derived suppressor cells to the tumor microenvironment. Pathogenic $\gamma\delta 1$ T cells are distinct from cytotoxic $\gamma\delta$ T cells, which are being used for adoptive T cell transfer or therapeutic engagement with bispecific antibodies. Depleting pathogenic $\gamma\delta 1$ T cells has the capacity to modulate both innate and adaptive immunity, and their distinct phenotypic and functional properties make them excellent potential therapeutic targets.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, as of the date of PureTech's most recently filed Registration Statement on Form 20-F, was comprised of 24 therapeutics and therapeutic candidates, including two that have received FDA clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential therapeutic benefits of our therapeutic candidates, our expectations regarding the potential mechanism of action and related benefits expected from LYT-210 based on the preclinical results presented at AACR, and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investors

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

EU media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and

the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUPUPUCUPGPPB